HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age45+
SponsorPopulation Health Research Institute
About this trial
The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assessment of major complications (e.g., mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke), delirium, length of stay, pain, and quality of life.
Eligibility criteria
Qualifiers
age ≥45 years;
diagnosis of hip fracture during working hours with a low-energy mechanism requiring surgery;
troponin elevation ( at least one troponin measurement above the upper limit of normal occurring from the time of hip fracture to the time of randomization); and
informed consent.
Disqualifiers
taking a therapeutic dose of an anticoagulant for which no reversing agent is available and the anesthesiologist or surgeon believe surgery within 6 hours of eligibility criteria met would not be safe;
patients on a therapeutic vitamin K antagonist with a history of heparin induced thrombocytopenia (HIT);
patients with peri-prosthetic fracture, open fracture or bilateral fractures;
patients requiring an emergency surgery for another reason (e.g., subdural hematoma);
Trial design
Treatments tested in this trial
- Accelerated medical clearance and surgery
Treatment groups
1,100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Population Health Research Institute
Lead sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborator
Source ClinicalTrials.gov